Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity

Oncotarget
Amy J C DohmenCharlotte L Zuur

Abstract

Treatment of advanced head and neck squamous cell carcinoma (HNSCC) is plagued by low survival and high recurrence rates, despite multimodal therapies. Presently, cisplatin or cetuximab is used in combination with radiotherapy which has resulted in minor survival benefits but increased severe toxicities relative to RT alone. This underscores the urgent need for improved tumor-specific radiosensitizers for better control with lower toxicities. In a small molecule screen targeting kinases, performed on three HNSCC cell lines, we identified GSK635416A as a novel radiosensitizer. The extent of radiosensitization by GSK635416A outperformed the radiosensitization observed with cisplatin and cetuximab in our models, while exhibiting virtually no cytotoxicity in the absence of radiation and in normal fibroblast cells. Radiation induced phosphorylation of ATM was inhibited by GSK635416A. GSK63541A increased DNA double strand breaks after radiation and GSK63541A mediated radiosensitization was lacking in ATM-mutated cells thereby further supporting the ATM inhibiting properties of GSK63541A. As a novel ATM inhibitor with highly selective radiosensitizing activity, GSK635416A holds promise as a lead in the development of drugs active in p...Continue Reading

References

Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·K Pekkola-HeinoR Grénman
Nov 1, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Muhyi Al-Sarraf
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J AdelsteinArlene A Forastiere
Oct 31, 2003·Cancer Cell·P Mathijs Voorhoeve, Reuven Agami
Mar 1, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Aimee R KreimerSilvia Franceschi
Jul 28, 2006·Genome Biology·Michael BoutrosWolfgang Huber
Apr 5, 2007·Nature Protocols·Nicolaas A P FrankenChris van Bree
May 16, 2007·Bioorganic & Medicinal Chemistry Letters·John A ChristopherMichael J Wilson
Oct 29, 2008·International Journal of Radiation Oncology, Biology, Physics·Fiona A DungeyAnthony J Chalmers
May 19, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jean-Pierre PignonUNKNOWN MACH-NC Collaborative Group
May 19, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Na ZhangReidar Grénman
Apr 23, 2010·Cancer Treatment Reviews·C PowellK J Harrington
Mar 2, 2011·Nature Reviews. Drug Discovery·Ricardo MacarronG Sitta Sittampalam
Jul 2, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Somaira NowsheenEddy S Yang
Oct 6, 2011·Molecular Cancer Therapeutics·Joana M SenraIan J Stratford
Oct 13, 2011·British Journal of Cancer·M Javle, N J Curtin
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
Nov 24, 2012·Nature Reviews. Cancer·Nicola J Curtin
Feb 19, 2013·Future Oncology·David R Raleigh, Daphne A Haas-Kogan
Nov 29, 2013·Current Topics in Medicinal Chemistry·David H DrewryWilliam J Zuercher
Nov 26, 2014·Annual Review of Medicine·Michael Goldstein, Michael B Kastan
Dec 17, 2014·Pharmacology & Therapeutics·Anika Maria Weber, Anderson Joseph Ryan
May 20, 2015·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Caroline V M VerhagenConchita Vens
Aug 13, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Monique C de JongAdrian C Begg
Nov 23, 2015·Molecular Cell·Mark J O'Connor
Dec 9, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano Maria MagriniSalvatore Grisanti
Jan 19, 2016·DNA Repair·Ayushi Guleria, Sudhir Chandna
Mar 1, 2016·Cancer Treatment Reviews·Bishal GyawaliYuichi Ando

❮ Previous
Next ❯

Citations

Dec 6, 2019·International Journal of Molecular Sciences·Hans LiewAndrea Mairani
May 20, 2020·International Journal of Molecular Sciences·Hans LiewAndrea Mairani
Jun 9, 2020·Expert Reviews in Molecular Medicine·Hannah L SmithNicola J Curtin
Jul 3, 2020·Expert Reviews in Molecular Medicine·Chumin Zhou, Jason L Parsons
Mar 19, 2019·Annual Review of Cancer Biology·Joshi NirajAlan D D'Andrea
May 2, 2020·Signal Transduction and Targeted Therapy·Rui-Xue Huang, Ping-Kun Zhou
Sep 25, 2021·Nature Structural & Molecular Biology·K StakyteK P Hopfner

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

Graphpad Prism
R

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Zain A HusainRoy H Decker
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Mohammad SakiH Peter Rodemann
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Ozden AltundagM Gunduz
© 2022 Meta ULC. All rights reserved